How is the pharmaceutical industry responding to the Covid-19 crisis? What more needs to be done towards securing the supply chain? What are some of the scientific and political obstacles to develop a vaccine?
“There’s a cost to manufacture locally, it would be higher and more expensive, but then you would have 300,000 more people with high wages, paying higher taxes than people collecting strawberries in the field.”
Guest bio: Pierre Laurin
Pierre Laurin is a senior executive with more than 35 years of experience in the pharmaceutical and biotechnology industry. He founded Prometic Life Sciences Inc. in 1994 and took the company public on the Toronto Stock Exchange in 1998. He served as President and Chief Executive Officer of the Corporation since its inception until December 2018 during which period he raised close to $1 billion in equity, debt financing and multinational funding. Mr. Laurin’s corporate development achievements include the successful closing of multiple licensing agreements and partnering agreements with multinationals, including two strategic agreements with the American Red Cross, which led to commercial applications and blood derived therapeutics. Mr. Laurin’s prior experience also includes positions with various pharmaceutical companies, including Nordic Laboratories (now Sanofi) where he played a pivotal role in the development and commercial success of Cardizem® in Canada and in the UK.
Pierre is Founder and Chairman at Ingenew Pharma.He also a board member of Innodem Neurosciences Inc., Innovon Pharmaceuticals Inc. and Invhealth Capital Inc. Mr. Laurin holds a Bachelor degree in Pharmacy and an MSc degree in Pharmaceutical Sciences from the University of Montreal.